Insider Selling: Century Therapeutics (NASDAQ:IPSC) CEO Sells 32,456 Shares of Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) CEO Brent Pfeiffenberger sold 32,456 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $0.45, for a total transaction of $14,605.20. Following the transaction, the chief executive officer directly owned 3,236,453 shares in the company, valued at $1,456,403.85. The trade was a 0.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Brent Pfeiffenberger also recently made the following trade(s):

• On Monday, November 17th, Brent Pfeiffenberger sold 32,456 shares of Century Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $14,605.20.
• On Monday, September 8th, Brent Pfeiffenberger sold 488 shares of Century Therapeutics stock. The shares were sold at an average price of $0.50, for a total value of $244.00.

Century Therapeutics Trading Up 5.5%

Shares of Century Therapeutics stock traded up $0.03 during trading hours on Wednesday, reaching $0.52. 885,739 shares of the company’s stock were exchanged, compared to its average volume of 787,216. Century Therapeutics, Inc. has a 52-week low of $0.34 and a 52-week high of $1.83. The company has a fifty day moving average of $0.54 and a 200-day moving average of $0.55. The firm has a market capitalization of $45.13 million, a price-to-earnings ratio of -1.62 and a beta of 1.80.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. Century Therapeutics had a negative return on equity of 10.01% and a negative net margin of 19.10%. On average, equities research analysts anticipate that Century Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 20th. Leerink Partnrs downgraded shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of Century Therapeutics in a research note on Wednesday, October 8th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down from $7.00) on shares of Century Therapeutics in a research report on Monday. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Century Therapeutics presently has an average rating of “Hold” and an average target price of $3.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in Century Therapeutics during the 2nd quarter worth $248,000. Two Sigma Investments LP lifted its stake in shares of Century Therapeutics by 59.2% during the third quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock worth $454,000 after purchasing an additional 338,902 shares in the last quarter. Squarepoint Ops LLC boosted its position in shares of Century Therapeutics by 483.1% in the third quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock worth $118,000 after buying an additional 195,573 shares during the period. Nuveen LLC purchased a new stake in shares of Century Therapeutics in the first quarter worth about $75,000. Finally, Acadian Asset Management LLC grew its stake in shares of Century Therapeutics by 101.2% in the first quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after buying an additional 142,953 shares in the last quarter. 50.20% of the stock is owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.